167 related articles for article (PubMed ID: 32724160)
1. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
2. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
[TBL] [Abstract][Full Text] [Related]
3. HER2-Targeted Antibody-Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget's Disease Models: In Vivo and Immunohistochemical Analyses.
Tokuchi K; Maeda T; Kitamura S; Yanagi T; Ujiie H
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884581
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.
Kitamura S; Yanagi T; Maeda T; Ujiie H
Cancer Sci; 2022 Feb; 113(2):802-807. PubMed ID: 34866279
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.
Vornicova O; Hershkovitz D; Yablonski-Peretz T; Ben-Itzhak O; Keidar Z; Bar-Sela G
Oncologist; 2014 Sep; 19(9):1006-7. PubMed ID: 25085898
[TBL] [Abstract][Full Text] [Related]
6. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Takahashi A; Tsutsumida A; Fujisawa Y; Fujimoto M; Yamazaki N
Clin Exp Metastasis; 2016 Oct; 33(7):687-97. PubMed ID: 27289366
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T
Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813
[TBL] [Abstract][Full Text] [Related]
9. Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Watanabe S; Takeda M; Takahama T; Iwasa T; Tsurutani J; Tanizaki J; Shimizu T; Sakai K; Wada Y; Isogai N; Nishio K; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):394-6. PubMed ID: 26856856
[TBL] [Abstract][Full Text] [Related]
10. The expression of HER-2 in extramammary Paget's disease.
Masuguchi S; Jinnin M; Fukushima S; Makino T; Sakai K; Inoue Y; Igata T; Ihn H
Biosci Trends; 2011 Aug; 5(4):151-5. PubMed ID: 21914949
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
12. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract][Full Text] [Related]
13. Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.
Lim BY; Guo Z; Lim JQ; Ko TK; Lee ECY; Kannan B; Lee JY; Lim AH; Li Z; Ng CC; Busmanis I; Chan JY
Orphanet J Rare Dis; 2024 Jun; 19(1):223. PubMed ID: 38831459
[TBL] [Abstract][Full Text] [Related]
14. KS-EMPD-1: a novel cell line of primary extramammary Paget's disease.
Ito T; Tanaka Y; Ichiki T; Kaku-Ito Y; Nakahara T
Hum Cell; 2023 Sep; 36(5):1813-1829. PubMed ID: 37432591
[TBL] [Abstract][Full Text] [Related]
15. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2
Nordmann TM; Messerli-Odermatt O; Meier L; Micaletto S; Coppetti T; Nägeli M; Kamarachev J; Kudura K; Freiberger SN; Rordorf T; Mangana J; Braun R; Dummer R
Oncotarget; 2019 Nov; 10(62):6647-6650. PubMed ID: 31803359
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease.
Mai R; Zhou S; Zhou S; Zhong W; Hong L; Wang Y; Lu S; Pan J; Huang Y; Su M; Crawford R; Zhou Y; Zhang G
Hum Pathol; 2018 Jul; 77():152-158. PubMed ID: 29630912
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of ERBB2 S310F mutation in extramammary Paget's disease.
Kusaba Y; Kajihara I; Myangat TM; Tanaka K; Kanemaru H; Sawamura S; Makino K; Aoi J; Masuguchi S; Fukushima S
J Dermatol; 2022 Sep; 49(9):e305-e306. PubMed ID: 35582767
[No Abstract] [Full Text] [Related]
18. Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients.
Kang Z; Zhang Q; Zhang Q; Li X; Hu T; Xu X; Wu Z; Zhang X; Wang H; Xu J; Xu F; Guan M
Int J Clin Exp Pathol; 2015; 8(10):13233-40. PubMed ID: 26722523
[TBL] [Abstract][Full Text] [Related]
19. Trop2 Expression in Extramammary Paget's Disease and Normal Skin.
Ito T; Tanegashima K; Tanaka Y; Hashimoto H; Murata M; Oda Y; Kaku-Ito Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299325
[TBL] [Abstract][Full Text] [Related]
20. MUC5AC expression correlates with invasiveness and progression of extramammary Paget's disease.
Hata H; Abe R; Hoshina D; Saito N; Homma E; Aoyagi S; Shimizu H
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):727-32. PubMed ID: 23581859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
